Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Conditions:   Borderline Resectable Pancreatic Adenocarcinoma;   Resectable Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Fluorouracil;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Biological: Nivolumab;   Drug: Oxaliplatin;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days